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Abstract: Strategies to enhance the already established doublet chemotherapy regimen for lung 
cancer have been investigated for more than 20 years. Initially, the concept was to administer 
chemotherapy drugs locally to the tumor site for efficient diffusion through passive transport 
within the tumor. Recent advances have enhanced the diffusion of pharmaceuticals through active 
transport by using pharmaceuticals designed to target the genome of tumors. In the present study, 
five patients with non-small cell lung cancer epidermal growth factor receptor (EGFR) negative 
stage IIIa–IV International Union Against Cancer 7 (UICC-7), and with Eastern Cooperative 
Oncology Group (ECOG) 2 scores were administered platinum-based doublet chemotherapy 
using combined intratumoral-regional and intravenous route of administration. Cisplatin 
analogues were injected at 0.5%–1% concentration within the tumor lesion and proven malignant 
lymph nodes according to pretreatment histological/cytological results and the concentration 
of systemic infusion was decreased to 70% of a standard protocol. This combined intravenous 
plus intratumoral-regional chemotherapy is used as a first line therapy on this short series of 
patients. To the best of our knowledge this is the first report of direct treatment of involved 
lymph nodes with cisplatin by endobronchial ultrasound drug delivery with a needle without 
any adverse effects. The initial overall survival and local response are suggestive of a better 
efficacy compared to established doublet cisplatin–based systemic chemotherapy in (higher) 
standard concentrations alone according to the UICC 7 database expected survival. An extensive 
search of the literature was performed to gather information of previously published literature 
of intratumoral chemo-drug administration and formulation for this treatment modality. Our 
study shows a favorable local response, more than a 50% reduction, for a massive tumor mass 
after administration of five sessions of intratumoral chemotherapy plus two cycles of low-dose 
intravenous chemotherapy according to our protocol. These encouraging results (even in very sick 
ECOG 2 patients with central obstructive non-small cell lung cancer having a worse prognosis and 
quality of life than a non-small cell lung cancer in ECOG 0 of the same tumor node metastasis 
[TNM]-stage without central obstruction) for a chemotherapy-only protocol that differs from 
conventional cisplatin-based doublet chemotherapy by the route, target site, and dose paves the 
way for broader applications of this technique. Finally, future perspectives of this treatment and 
pharmaceutical design for intratumoral administration are presented.
Keywords: cisplatin, lymph nodes, chemotherapy, intratumoral, lung cancer
Introduction
Lung cancer treatment still remains a challenge. In the last decade an effort has been 
made to identify the mechanisms and pathways of lung cancer.1,2 Pharmacoethnicity 
in association with pharmacogenomics has also been investigated as the genetic 
mutations of lung cancer differ among populations and therefore several 
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targeted therapies present a higher rate of eff iciency, 
as is the case with epidermal growth factor receptor 
mutation (EGFR).3–5 Pharmacogenetics have also been 
investigated for conventional chemotherapy in lung cancer 
in an effort to identify different pathways and mechanisms of 
acquired resistance to conventional chemotherapy.6,7 Targeted 
therapies have been approved as first line treatment for 
specific genetic mutations and many pathways are still under 
investigation.8 However, doublet chemotherapy still remains 
the cornerstone of treatment for many patients.9
Chemotherapy drugs present non-specific cytotoxic activ-
ity, which in many cases induce adverse effects from systemic 
administration. Patients have to stop their treatment and the 
national health systems are affected by the additional hospital-
ization days and drugs administered.10 In an effort to enhance 
the efficiency of conventional chemotherapy, several studies 
have investigated the addition of immunomodulatory agents 
with conventional chemotherapy and/or anti-vascular endothe-
lial growth factors with targeted chemotherapy.11–14 However, 
systemic side effect prevalence still remains the same.
Another conceptual approach, ie, the locoregional admin-
istration of chemotherapeutics has been promoted by many 
groups either in the form of intratumoral chemotherapy 
(ITC),15–17 brachytherapy,18 photodynamic therapy,19 mechanic 
debulking,20,21 and aerosol chemotherapy.22–24 Locoregional 
therapy uses chemicals, genes, biologics, free or formulated 
drugs, and novel drug carrier systems, as a single therapy or 
with radiation therapy,25–29 thermal,22,74 or non-thermal local 
ablative methods. These studies were mostly intended to 
establish the safety and efficacy of locoregional therapies and 
investigate whether higher drug concentration could increase 
efficiency and decrease or prevent systematic adverse effects. 
Intratumoral drug administration was also investigated as a 
method to sensitize the tumor to radiotherapy and systematic 
chemotherapy.30 Nearly 30% of newly diagnosed patients with 
lung cancer will develop respiratory distress, bleeding, atelecta-
sis, and post-obstructive pneumonia due to partial or complete 
airway obstruction.31 The tumor core consists of chemotherapy 
resistant tumor cells and intratumoral chemotherapy has been 
observed to sensitize these cells by delivering selected drugs 
into different parts of the core with radioactive coils and other 
agents for brachytherapy.30,32–34 In particular, it was observed 
that nanocarriers for chemotherapy drugs lead to improved 
drug diffusion and sustain release. In addition, brachytherapy 
studies presented data were the radiation emitted from the coils 
was only cytotoxic to the site of inplantation.30,35 It has also 
been observed that local tumor response is accomplished more 
quickly with local intratumoral drug administration.16,36
Moreover, there are obstacles that have to be bypassed 
with these treatment techniques, such as: (a) increased inter-
stitial fluid pressure, (b) local hypoxia, (c) heterogeneous 
distribution of drug formulations due to abnormal vascular 
architecture, (d) extracellular matrix with collagen, elastin, 
fibroblasts, and (e) structural abnormalities within the cen-
ter of the tumor. There are two principal methods of drug 
permeation of the tumor as a sum effect of diffusion and 
distribution within the tumor: active and passive transporta-
tion, which can be combined with a physical (pre)treatment, 
like heating the device to enhance uptake or diffusion,37–39 
or with a cooling device.40 Several formulations have been 
investigated either with passive or active transportation in 
order to investigate their efficiency. In addition, carriers 
have been added to several pharmaceuticals to prolong their 
local release and diffusion rates.41,42 Nanocarriers have pro-
vided an effective method for drug accumulation within the 
tumor due to the enhanced permeability and retention effect 
(EPR) effect.43 The EPR effect has been also observed to be 
enhanced with the addition of polyethylene glycol (PEG) 
stealth molecules,44 and controlled by heat shock protein 
32 and carbon monoxide.45 The present study illustrates our 
initial experience with intratumoral chemotherapy compared 
to previous published studies and we propose future avenues 
for applications of this methodology.
Patients and methods
Patients and study design
Five patients stage IIIa–IV, performance status 2 (PS2)  unfit 
for surgery, radiation, and chemotherapy were included in the 
trial. The trial was initiated in May 2009 and was approved 
by our investigational review board (IRB; Table 1). One 
additional patient was excluded from the trial when she 
was diagnosed with mammarian carcinoma stage IV with 
a stenotic tracheal metastasis and hypercapnia $60 mmHg 
unfit for treatment with laser or argon-plasma-coagulation 
or radiation; however, she was treated along the same line 
of this protocol only with slightly different ITC mixture, 
adding 2 mg mitomycin to 10 mg cisplatin, and observed 
upon follow up. The staging was decided according to the 
sixth edition of tumor node metastasis (TNM) classification 
of non-small cell lung cancer (NSCLC) as the trial took 
place in 2009 and 2010. All patients had relatively adequate 
renal function allowing for the administration of at least 
70% of the dose defined intravenous standard platinum 
doublet protocol (or alternatively area under the curve 
[AUC] 4 in case of carboplatin; defined by a level of serum 
creatinine of Value1.5 mg/mL), hepatic enzymes (bilirubin 
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of Value1.5 mg/dL), and hematologic function (absolute 
neutrophil count of 1.5 × 103 mm3 and platelet count of 1.0 
× 105 mm3). Patients included had symptomatic obstruction 
of the trachea or of a major bronchus secondary to inoperable 
histologically confirmed NSCLC. The patient population in 
this study included only patients with disease confined to 
one hemithorax and with the major tumor involvement in the 
thorax. Two cases with Stage IV NSCLC showed single bone 
metastasis in upper arm respectively in thigh. For such cases, 
the therapeutic strategy was to relieve symptoms from the 
bronchial tumor and to address metastatic bone deposit with 
radiation therapy and bisphosphonates according to standard 
oncologic care. Nearly complete airway obstruction, superior 
to 50% occlusion of at least one major airway was required 
for inclusion into the study. Other criteria were: isolated lobar 
obstruction was included only if it was believed to contribute 
to respiratory insufficiency, chronic (or continuous) bleeding 
worsening the respiratory situation or post-obstructive 
pneumonia, or all these conditions together. Patients with 
small cell carcinoma were excluded, based on anticipated 
rapid response to systemic chemotherapy or irradiation or 
both that these patients often experience.46
All patient treatment sessions were recorded in order to 
evaluate the therapeutic protocol (Figures 1–6). Criteria for 
exclusion were: pregnancy or child-bearing potential without 
using contraceptive methods, concurrent highly septic situations 
due to poststenotic pneumonia infections (ie, requiring intra-
venous antibiotic therapy was allowed), an unstable or serious 
concurrent medical condition (eg, recent myocardial infarction 
and superior vena cava syndrome), recent major surgery, or 
large-field radiation therapy or chemotherapy in the month 
before entry. Patients were not allowed to receive any concur-
rent radiotherapy to the lungs, immunotherapy or investigational 
agents while on the study. These criteria were chosen based on 
previous publications (Table 2).16,47 Written informed consent 
was obtained from each patient before study enrollment. Patient 
characteristics upon admission are presented in Table 1.
Dose schedule and technical aspects
The protocol was based on previous publications in the field 
of intratumoral chemotherapy.16,36,46–48 Previous groups treated 
their patients with cisplatin 0.5%–4% ITC. In Germany, 0.5% 
cisplatin is the concentration for intravenous administration; 
although uncommon, other cisplatin concentrations are avail-
able through the hospital’s dispensary when buying cisplatin 
as a salt. It is believed that upon intratumoral bolus injection, 
cisplatin will diffuse systemically via lymphatic draining ves-
sels and lymph nodes; such drainage may reach sentinel lymph 
nodes that would be exposed to the drug as a consequence of 
ITC and at a higher drug concentration than possible with intra-
venous administration of the same cisplatin amount (Figure 5). 
Figure 1 X-ray from patient 1. 
Notes: (A) X-ray upon diagnosis. (B) after one session (1 month). (C) and after two sessions (6 weeks after diagnosis).
Table 1 Patient characteristics
Patient  
stage
ECOG Local 4-week 
response
Survival 
(days)
Histology
1. IIIb (cT4N2Mx) 2 PR- 311 Squamous
2.  IV (cT3-  
4NxM1b)
2 PR+ 429 Squamous
3.  IIIb (cT4N2M0) 2 PR+ 496* Squamous
4.  IV (cT3-  
4N2M1b)
2 PR- 365 Adeno
5.  IIIa (cT4N1M0) 2 NC 552* Adeno
6.  Mammarian  
CA IV
2 Local CR 319 Adeno
Notes: *Alive upon end of follow-up, other patients died due to cancer-related 
death. Average PR+ overall survival: 463 days; average PR- overall survival: 338 days. 
PR+: reduction of .50% of initial volume; PR-: reduction of 25%–50% of initial 
volume.
Expected median survival according to UICC 7 in ECOG 0–1 patients: IIIa 1/5, IIIb 
2/5, IV 2/5 = ((1*14 m) + (2*10 m) + (2*6 m))/5 = 9.2 months = 276 days.
Achieved median survival in this ECOG 2 group along our protocol = 13.2 m = 397 
days: This means a surplus of 43.8% median survival in comparison to expected 
survival.
Abbreviations: PR, partial response; ECOG, Eastern Cooperative Oncology Group; 
NC, no change; CR, complete response; Adeno, adenocarcinoma; CA, carcinoma.
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As lymph node involvement in lung cancer is a major concern 
for local recurrence, we added the direct treatment of involved 
lymph nodes by drug delivery through a transbronchial needle 
aspiration (TBNA)-needle of an endobronchial ultrasound 
(EBUS)-probe to enhance the efficacy over ITC only. This drug 
delivery by an EBUS-needle (EBUS-transbronchial needle dos-
ing [TBND]) is aiming at six passes per lymph node to optimize 
the permeation of the drug. We have chosen this number as six 
passes are the optimal number for EBUS-TBNA to get repre-
sentative results of the whole lymph node volume.
A huge point of contention for the use of ITC is the under or 
over-dosing due to the leakage or backflow of drug. Such “loss” 
if not quantified makes it very difficult to relate the dose to the 
effect over a tumor or target volume unit. We think that even in 
the case that intratumoral-volume leaks out of the tumor very 
easily as a so called “downstream effect”, this intratumoral-loss 
cisplatin dose will be reabsorbed by the alveoli and mucosa 
in other lung areas and will act as a systemic administration. 
In other words, ITC that uses aqueous platinum analog offers 
the advantage of very high concentrations (eg, up to 70-fold 
higher compared to the same amount of carboplatin given intra-
venously in ITC with polyethylene glycol (PEG)-carboplatin)49 
with less systemic cytotoxicity but in the end it resembles an 
established intravenous split schedule: the timely separation of 
intratumoral and intravenous administration leads to the well-
known efficient intravenous split cisplatin protocols with two 
dosages typically 6 to 7 days apart and therefore this dosing 
regimen makes sense.50
ITC has been demonstrated in animal models with lung 
cancer to induce a positive antitumor immunoresponse;51 
meaning a significant reduction in tumor mass different 
than the main site directly treated by ITC. The same has 
Figure 2 Patient 2 upon diagnosis. 
Notes: (A) Vertical computed tomography image upon diagnosis with ans without contrast. (B) X-ray upon diagnosis. (C) bronchoscopy image upon diagnosis.
Figure 3 CT images from patient 2. 
Notes: (A and C) CT upon diagnosis. (B and D) CT after 10 weeks.
Abbreviation: CT, computed tomography.
Figure 4 Patient 2 bronchoscopy findings upon diagnosis and after 10 weeks of 
therapy including four ITC-sessions and three reduced systemic carboplatin doublet 
applications. 
Notes: (A) Bronchoscopy image upon diagnosis. (B) Bronchoscopy image after 
local intratumoral treatment. 
Abbreviation: ITC, intratumoral chemotherapy.
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been proven in human beings using other local treatment 
modalities in different cancers.52 This effect is believed or 
has been partly proven to be caused by demonstrating vast 
amounts of tumor cell debris toward immunocompetent 
cells, which are stimulating the immune system to use these 
“specific” antigens to induce a “specific” antibody reaction; 
eg, auto-vaccination triggered by local treatment modalities. 
The cornerstone of these mechanisms is an intact competent 
immune system which could be negatively influenced by 
acute administration of intravenous chemotherapy. This is 
the second reason to separate intravenous from intratumoral 
administration timing for the first 5–10 days of treatment.
A major factor affecting ITC-efficacy is the distribution 
of the drug intratumorally. We treated the mass from all pos-
sible directions: from endoluminal or from transthoracical 
direction if feasible under ultrasound or C-arm fluoroscopy 
guidance due to local anatomy. We used direct central needle 
insertion in lobar stenosis (with atelectasis, chronic bleed-
ing, and/or post-stenotic pneumonia) and in central airway 
stenosis .50%. Especially in lobar stenosis, the maneuver-
ability of the needle in the peripheral site is highly reduced; 
therefore, the needle tip was placed in the most distant part 
of the tumor and then retracted 0.5 cm delivering at each 
point a maximum of 1 mL ITC-drug. This approach was only 
allowed if the needle path was clear inside the inner two thirds 
of a post-stenotic atelectasis which could represent a tumor 
portion. In the exophytic parts of mainly central tumors, we 
additionally directly injected intratumorally and, furthermore, 
surrounded the exophytic parts on the mucosal layer with 
small injections (1 mL) intramucosally/superficially around 
the tumor neck aiming at closing a circle around the tumor 
neck at this layer. In case of mixed intra-extrabronchial 
stenosis with a transmucosal part of bulk and/or involved 
lymph nodes we treated this part of the tumor by EBUS-
TBND. In lymph nodes, we aimed at six passes with differ-
ent angulations for EBUS-TBND. For masses that abutted 
the thoracic wall, we used ultrasound guided percutaneous 
transthoracic drug injection (transthoracic ultrasound [tts] 
ITC) through only one transthoracic puncture receiving the 
needle tip to the most distal part of the ultrasound picture of 
the mass and injecting 1 mL ITC-drug after each 0.5 cm pull-
ing step back toward the puncture point. This procedure was 
repeatedly performed in different angulations with 30 degrees 
difference in a three-dimensional manner and under bron-
choscopy for controlling and calculating the “loss” amount 
of ITC leaking out of tumor mass and dispersing rapidly 
down toward the central airways – the so called downstream 
effect of ITC. The downstream effect may result from the 
typically inhomogeneous spongy tumor structure or separated 
by septa, layers, or from puncturing of bronchioli lumen 
still patent within the tumor. In order to better visualize the 
downstream effect, we colored the cisplatin-ITC with indigo 
carmine dye (0.5 mL/10 mL drug volume). If a downstream 
effect occurred, the injection was stopped, the needle posi-
tion was changed by retracting 1 cm, followed by the next 
injection of 1 mL until the subpleural area adjacent to the 
insertion point was reached. Then a new needle pathway with 
different angulations was started at the most distal point of 
the ultrasound picture. In case visualization by ultrasound 
was not possible we used different angulations under c-arm 
fluoroscopy control. All this was to achieve a best individual 
distribution of the ITC-drug to cover up the major part of the 
tumor volume and involved lymph nodes.
Furthermore, the calculation of the ITC-drug volume was 
done along the lines of the formula by Monga53 using the help 
of the computed tomography (CT)-scans (in mL ITC-drug):
Volume =  0.5*maximum height*maximum width 
 *maximum depth (1) 
covering approximately 1 mL of tumor with 1 mL of 
ITC-drug. In this study, we were adding the volume for 
Airway
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Figure 5 Intratumoral chemotherapy model. 
Notes: After the local administration, tumor necrosis is observed and 
micrometastasis occurs through the local abnormal vascular architecture and 
diffusion through the interstitial fluid. 
Abbreviation: IF, interstitial fluid.
iv iv iv
Start------ ------ ------ ------ ------ ------ ------ ------7d
ITC ITC ITC ITC ITC ITC
14d 21d 28d 35d 42d 49d 56d
Figure 6 Scheme of proposed intratumoral protocol. Timing of intravenous 
4-week-cycle with weekly intratumoral chemotherapy. 
Abbreviations: d, day; ITC, intratumoral; iv, intravenous.
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involved lymph nodes which were measured by EBUS 
during the diagnostic TBNA in addition to the CT-scans 
prior to therapy. In case a downstream effect was observed, 
we summed up each observed 1 mL (meaning suddenly 
rapid unmeasured droplets) of “lost” ITC-drug after planned 
injection of 1 mL ITC and added this amount afterwards to 
another “additional” path with a different angulation until 
the pre-therapeutic calculated ITC-volume was reached. 
The consequence of this approach was that in the patients 
with a downstream effect more ITC-volume than previously 
calculated was used. In reality, this was observed in two 
patients with no more than 10% additional volume only in 
the transthoracical approach. We restricted ourselves to a 
maximum of total ITC volume 2-fold of the pre-therapeutic 
calculated ITC-volume. A CT-scan for reevaluation and recal-
culation of the ITC-volumes was repeated after two complete 
intravenous cycles encompassed by four to six administra-
tions of ITC. The minimal goal in these very sick patients 
Table 2 Intratumoral therapy experience
Author Methodology Subjects Cancer cells/ 
tissue
Response Nanoparticles Carriers Reference
Jia et al Intratumoral plus 
doxorubicin 
magnetic field
In vitro/in vivo Lewis lung cancer √ Magnetic Fe3O4 PLGA 27
Akeda et al OK-432 In vivo Squamous lung 
carcinoma
√ – – 80
Li et al Multifunctional 
theranostic 
liposome 
drug delivery system 
plus doxorubicin
In vitro/in vivo Squamous cell 
carcinoma-4 tumor 
cells
√ Magnetic Liposomes 62
Goldberg et al Review Review Review Review Review Review 51
Brincker et al Review Review Review Review Review Review 61
Celikoglu et al 5-fluorouracil, 
mitomycin, 
methotrexate, 
bleomycin, 
mitoxantrone, 
cisplatin
Patients Lung cancer √ – – 16 
36 
46 
47 
48 
56
Fujiwara et al Intratumoral-P53 Patients Lung cancer √ – – 25
Abbreviations: OK, lyophilized incubation mixture of group A Streptococcus pyogenes of human origin; PLGA, poly(lactic-co-glycolic acid).
Table 3 Effects and safety features
Patient Adverse effect Positive effect Comment
1 Enforced bleeding after 1 ITC  
(infiltration of the LLL-vein)
Stopped moderate chronical bleeding  
after second ITC, no recurrence of  
bleeding.
PR– (main symptom was bleeding).
2 Vomiting, nausea, and hematotoxicity.  
(1800 Leuc./uL) after first ITC with  
100 mg cisplatin.
Could swallow again after second ITC  
stopping muscle waste, walks alone.
PR+; possible infiltration of the esophagus 
in reference to thorax-CT. Hematotoxicity 
as a proof of systemic effect.
3 None Relief of dyspnoea and mucous retention,  
stopped chronical bleeding after first ITC.
PR+
4 None Relief of retention, reduced pCO2. PR-; heavy smoker until death.
5 Acute cytotoxicity in the complete ROL as COP  
(including S3) radiological without clinical relevance  
and spontaneous regression without any lasting  
damage; needle was steered from inside at the  
inner 2/3 margin of the lobar atelectasis which  
occluded orifice S1+2 in ROL.
None (slightly less back pain). NC
6 Fever for 3 days after ITC. Local CR, no longer bleeding or  
retention.
Local CR; acute short mediastinitis? 
Breast cancer stage IV with tracheal  
metastasis (out of protocol).
Abbreviations: CT, computed tomography; ITC, intratumoral chemotherapy; CR, complete response; COP, cryptogenic organising pneumonia; Leuc, leucocytes; ROL, 
right upper lobe (rul); PR, partial response; pCO2, partial carbondioxide measurement; LLL, left lower lobe; S, subsegment; NC, no change.
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was to administer two cycles intravenous platinum doublet 
every 3–4 weeks encompassed with at least four sessions 
ITC. We hoped to achieve four cycles intravenous doublet 
encompassed by 8–12 ITC-administrations timely separated 
as mentioned above if the patient was willing to do so and 
if the local (meanwhile regressed) anatomy was feasible to 
inject. One potential limitation of this protocol was the fact 
that these sick patients had to be treated weekly for the ITC-
administration with aqueous cisplatin. In palliative patients, 
too much time inside the hospital should be avoided.
Previous experience of intratumoral administration was 
30–40 mg aqueous cisplatin demonstrating good tumor reduc-
tion and no adverse effects.16,36,46–48 Therefore we used cisplatin 
1% for smaller masses and 0.5% cisplatin concentration for 
larger masses to realize a compromise between injected vol-
ume and drug amount per tumor volume unit for optimization 
of drug distribution and tumor coverage with ITC. It has to 
be mentioned that it was allowable to use more than 40 mg 
cisplatin per ITC-session, but not more than the (theoretical) 
70% standard cisplatin intravenous amount in these very sick 
patients. We restricted ourselves therefore to the maximal dose 
of 100 mg cisplatin per ITC-session. In reality, this was only 
used in one ITC-session, all other ITC-sessions were done with 
10–50 mg cisplatin in total (average 24 mg cisplatin).
The drug injection rate for ITC was between 1 and 
5 mL/minute: if the downstream effect occurred we stopped 
injection at the preceding injection point and reduced our 
velocity to 1 mL/minute at the next injection point after 
retraction of the needle. If there was no downstream effect 
with 1 mL/minute in the preceding injection point we elevated 
our injection velocity to 5 mL/minute in the following injec-
tion point after retraction. All this was meant to optimize 
the coverage of ITC-volume in the mass and the time per 
treatment session. The treatment times for an ITC-session 
covering tumor mass and node(s) (average mass dimensions: 
7 cm; average number of nodes: 2) was between 25 and 
60 minutes (average 38 minutes).
Pharmaceuticals
The following pharmaceuticals were used for weekly intra-
tumoral chemotherapy 5–10 days apart from the intrave-
nous administration: cisplatin/hospira solution for infusion 
100 mg/100 mL vial BT × 1 vial × 100 mL (Hospira UK Ltd, 
Queensway, Royal Leamington Spa, Warwickshire, UK) in 
concentrations between 0.5% and 1%.
For intravenous chemotherapy, 70% of a standard 
platinum analog containing doublet scheme repeating every 
3–4 weeks with the following drugs was used: cisplatin 
or carboplatin and one of the following drugs GEMZAR® 
(Lilly USA LLC, Indianapolis, IN, USA; 200 mg/1 g vial), 
etoposide, and vincristine.
The intravenous administration was separated from 
ITC by 5–10 days. The protocol aimed to treat these very 
sick patients was with at least two cycles of intravenous 
administration encompassed by 4–6 intratumoral adminis-
trations, if feasible due to local anatomy. The intravenous 
combination scheme was chosen based on the performance 
status of the patients. Putting intravenous and intratumoral 
administrations together means that between two intravenous 
administrations it was possible to give an additional two or 
three ITC-administrations (Figure 6).
Specific treatment effects  
and complications
In summary, there was no severe adverse event in a total 
of 22 ITC-sessions even in an ITC with 100 mg cisplatin 
showing only a one-time moderate hematotoxicity with 1800 
leukocytes/mL. This is striking as a proof of the concept that 
ITC either passed through the lymphatic vessels or was down-
streamed or reabsorbed by the bronchial mucosa and alveoli 
to become systemically active. It is worth mentioning that for 
all directly visible tumor masses the first injection with ITC, 
regardless of the approach (endoluminal or transthoracic), 
changed the tumor color to pale or white almost immediately 
and sometimes after the injection of only 1 mL. This appears 
to be an acute interruption of the perfusion or a “shock reac-
tion” of the tumor. Another interesting observation was the fact 
that in patients with chronic bleeding from the tumor or from 
peritumoral vessels, the bleeding stopped after only one or two 
ITC-sessions. No acute local toxic effect in the mucosa or in 
the healthy central airways could be identified; no late stenotic 
process after ITC-sessions occurred either. Similar findings 
have been reported in previous studies (Table 1).16,36,46–48
Discussion
Intratumoral injection of chemotherapeutics is an efficient 
and safe local therapeutic method. ITC as adjuvant therapy 
using the protocol described herein showed, as in other 
ITC-studies, an expected relief concerning the acute local 
problems caused by stenosis, bleeding, or atelectasis in four 
of five NSCLC patients in the protocol and in one patient 
(out of protocol) with mammarian cancer and tracheal 
metastasis.32,42,44,54–60 Moreover, this trial demonstrated for 
the first time that direct treatment of involved lymph nodes 
with ITC by aqueous cisplatin simultaneously to the tumor 
mass is possible and safe. As the results concerning debulk-
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ing are similar to those of other studies, loss of ITC-volume 
as a downstream effect seems to be negligible.32,42,44,54–60 
Such a downstream effect was only seen with small “loss” 
volumes in two patients only when applying transthoracical 
ITC. It is worth mentioning that to the best of our knowledge 
we applied for the first time this protocol using a dye and 
simultaneous bronchoscopy during transthoracical approach 
of ITC to control this unintended effect of downstreaming and 
thereby optimized the application of aqueous cisplatin for ITC 
in a transthoracical approach. A big difference in this study 
compared to other studies was that we took this approach in 
very sick ECOG 2 patients who were not eligible for standard 
oncologic care procedures. Under general conditions these 
patients would have only received best supportive care with 
a survival prognosis around 3 months. Even comparing these 
very sick patients with the actual database UICC 7, which is 
referred to as ECOG 0–1 patients treated in general with full 
standard dose of intravenous platinum doublet schedules, it 
appears as if this simple and less toxic protocol is superior to 
standard intravenous regimens with respect to not only qual-
ity of life but as well to overall survival measured as cancer 
related death. For now, the technique described herein using 
free drug is applicable everywhere and induces relatively low 
costs compared to the so called personalized tumor treatment 
with modern drugs like tyrosine-kinase-inhibitors.
However, there is much room for optimization and further 
investigation into the formulations of the drugs administered in 
this study is warranted.36,48,51,61 First, passive or active  targeting 
should be explored. Active targeting has the advantage that 
the formulation will bind locally to tumor cells and will not 
leak through the abnormal vascular structures. Toward this 
end, several efforts have been made to identify molecules that 
can target actively with or without an additional chemotherapy 
agent the tumor mutations.62 Several molecules/pathways have 
been investigated in lung cancer patients, such as Galectin-3 
and Cyclin D1, however there are still no candidates for active 
targeting. This is an example where molecules and pathways, 
although similar in different tumors, play different roles.63 In 
an effort to identify new methods of sustaining drug release, 
co-encapsulation of magnetic Fe
3
O
4
 with chemotherapeutic 
agents have been investigated.27,64 However, although this 
method of local drug entrapment is effective in small animals, 
it can be lethal in larger (.dogs) as a larger magnetic field 
is required. Also, extravasation has been observed when the 
drug formulation is injected superficially. Another method 
of drug release which is under investigation by Patrick Le 
Pivert (Interventional Drug Delivery Systems and Strategies 
[ID2S2], Medical Cryogenics, Jupiter, FL, USA) is intratu-
moral drug injection while simultaneously freezing tissue 
locally.40 Another method for temporary local entrapment 
based on passive transportation is the addition of epinephrine 
with the cisplatin drug formulation.65 The pH release system 
has also been investigated with chemotherapy, the principal 
theory being that at a low pH (,6.5; acidic environment) the 
formulated complex releases the encapsulated drug.27 In the 
study by Callahan et al,66 for the first time a pH responsive 
genetically encoded drug release nanoparticle system was 
engineered. This pH delivery system is designed to release 
drug formulations in the mildly acidic environment that pre-
vails in the extracellular matrix (ECM) of many solid tumors. 
Temperature-sensitive gels as an intratumoral sustain release 
system were also investigated (β-Lapachone). This formula-
tion can be combined in a drug formulation complex and act 
as the trigger for the drug release.28
Furthermore, a new methodology for evaluating drug 
formulations for intratumoral delivery has to be pursued. 
Specifically, as previously presented in gene therapy studies, 
prediction models for drug diffusion within the tumor have to 
be established before initiation of drug administration.67 The 
ITASSER ([http://zhanglab.ccmb.med.umich.edu], Ann Arbor, 
MI, USA) software is an established evaluation method with 
many applications that has been used in previous studies.67,68
Moreover, several other studies were performed using the 
ITASSER methodology; however, they were all implemented 
in other organs, but they did demonstrate both efficiency and 
safety.30 Radioactive wires have been applied with or without 
the combination of a chemotherapy agent. These studies 
used nanoparticles for better tumor penetration and diffu-
sion (Table 4).42,44,64,69,70 In these studies, it was observed that 
healthy tissue was not affected by this therapy. In a study by 
Watson et al70 an ultrasound methodology was investigated to 
efficiently deliver nanoparticles in epithelial and epithelial-
mesenchymal transition tumors. Nanoparticles have also 
been used in association with thermal ablation as a method 
for enhancing drug delivery/diffusion within the tumor and 
to enhance local cytotoxicity.29 Intratumoral gene therapy was 
also investigated with or without the addition of a chemother-
apy agent and or radiotherapy.44,67,71–73 In a gene therapy study 
by Hanna et al72 the methodology of intratumoral injection was 
presented making this study an example for others to follow. 
In these studies, it was observed that larger particles have a 
higher probability of being absorbed by  macrophages. New 
photo-absorbent agents have also been tested as intratumoral 
therapy.  Indocyanine green was conjugated with phospholipid-
polyethylene glycol-monoclonal antibody (PL)-PEG-mAb 
in order to create a formulation with slow clearance times. 
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This drug formulation has numerous  applications for several 
cancer types.74 Moreover, fibers bearing chemotherapy agents 
were constructed for intratumoral therapy and were evaluated 
for their pharmacokinetic profile and efficiency in vitro and 
in vivo.75,76 The fibers presented efficient tumor control and a 
correlation with radiolabelled coils was established.
Immunotherapy as intratumoral therapy has also been 
investigated: (a) Propionibacterium acnes induces immune-
stimulation by increasing interleukin-12, tumor necrosis 
factor-α, and interferon-γ,77 (b) secondary lymphoid 
chemokine and unmethylated cytosine-phosphorothioate-
guanine-oligodeoxynucleotide were used to mobilize lympho-
cytes and dendritic cells and increased the infiltration of CD4+ 
T-cells and CD11c+ cells in the tumor mass with observed 
reduction in tumor mass,78 (c) hu14.18-interleukin-2 admin-
istration resulted in increased natural killer (NK) group 2, 
member D receptors on intratumoral NKG2A/C/E+NKp46+ 
NK cells,79 (d) OK-432 efficiently suppressed metastatic 
squamous cell carcinoma lesion by inducing interferon-γ and 
tumor necrosis factor-α,80 (e) pre-treatment with cyclophos-
phamide and oligodeoxynucleotides plus rituximab enhanced 
immune activation against tumor cells and reduced tumor evo-
lution,81 (f) dendritic cells and dendritic cells plus cyclophos-
phamide or paclitaxel at low doses enhanced immune system 
activation,82,83 (g) anti-gal antibody injection.84 Furthermore, 
several biomarkers were used specifically in intratumoral 
therapies as independent predictive factors, such as T cells 
and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, an inhibitor of lovastatin, as a formulation that 
blocks local metastasis after irradiation.85
Recently, sorafenib, a multi-targeted tyrosine kinase inhibi-
tor, was used in an effort to modify interstitial fluid pressure 
(IFP) and vascular density.86 It was observed that sorafenib and 
imatinib both decreased IFP, increased vascular endothelial 
growth factor, human placental growth factor, stromal cell-
derived factor α, and decreased soluble vascular endothelial 
growth factor receptor-2, and, consequently, disease control 
was observed.
Finally, lymphatic vascular circulation biology plays a key 
role in micrometastasis formation. Tumor cells are mobilized 
from the tumor site to the lymphatics before returning to the 
systemic vascular circulation.87–90  Lymphatics have thin walls 
and low pressure and, in addition, they collect fluid of various 
substances from the interstitium and return it to the vascular 
circulation.53,90 The lymphatics also act as a filter for tumor 
cells and although they redeposit cancer cells they additionally 
destroy cancer cells using their immunomodulatory activity.87 
Sentinel lymph node mapping has been well described with 
tracer substances. Specifically, it was observed that when a tracer 
was injected through the bronchial wall the tracer was trans-
ported to the regional lymph nodes by local lymphatic drainage 
within 20–60 minutes depending on the site of injections and 
available lymph node vasculature.5,56,91,92 The same principle is 
in effect with regard to cytotoxic drug tissue injection.
At this point, the authors would like to state that the 
major limitation of this study is the small number of 
patients; however, statistically significant overall survival 
was observed P = 0.048 (Table 1). Thus, our data provide 
us with the necessary support to evaluate this modality in a 
larger prospective study.
Based on our data and published literature we are confi-
dent that intratumoral chemotherapy should be considered 
for the following uses:16
a. As a debulking tool in central NSCLC with a high efficacy 
rate of .75% after four weekly sessions of ITC, demon-
strated efficacy in 378 published patients including this 
trial over two decades in different countries;32,42,44,54,55–60
b. As an adjunct to standard therapies even now in healing 
trials in PS2-patients with central obstructive palliative 
NSCLC;
c. Five studies, including this trial using ITC as an adjunct 
to different standard therapies, are observational studies 
using different modalities (to the best knowledge 
Phase IIb), but they have shown in 68 patients with 
NSCLC IIIa–IV unexpected median survival with an 
improvement of 21%–78% compared to UICC 7 data 
(4–6 months in total);42,57,59,60
d. Direct treatment with ITC (cisplatin 0.5%–1%) of central 
tumor mass and involved lymph nodes by EBUS-TBND 
is possible without severe adverse effects;
e. Direct treatment with ITC (para-toluenesulfonamide) of 
peripheral nodules in combination with standard carboplatin 
doublet chemotherapy shows very promising results;60 and
f. ITC as an adjuvant local procedure in combination with 
standard, timely separated intravenous protocols should 
be tested against adjuvant radiotherapy especially in 
regards to (reduced) toxicity and survival.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Hinoda Y. [Molecular targeted cancer therapy and genetic tests – 
chairman’s introductory remarks.] Rinsho Byori. 2012;60(10):967–968. 
Japanese.
2. Domvri K, Darwiche K, Zarogoulidis P, Zarogoulidis K. Following the 
crumbs: from tissue samples, to pharmacogenomics, to NSCLC therapy. Transl 
Lung Cancer Res. 2012. DOI: 10.3978/j.issn.2218-6751.2012.12.06.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
580
Hohenforst-Schmidt et al
Drug Design, Development and Therapy 2013:7
 3. Saijo N. The role of pharmacoethnicity in the development of 
cytotoxic and molecular targeted drugs in oncology. Yonsei Med J. 
2013;54(1):1–14.
 4. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenet-
ics and pharmacogenomics: role of mutational analysis in anti-cancer 
targeted therapy. Pharmacogenomics J. 2012;12(4):277–286.
 5. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor 
receptor-targeted immunoliposomes significantly enhance the effi-
cacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24): 
11631–11638.
 6. Giovannetti E, Toffalorio F, De Pas T, Peters GJ. Pharmacogenetics of 
conventional chemotherapy in non-small-cell lung cancer: a changing 
landscape? Pharmacogenomics. 2012;13(9):1073–1086.
 7. Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ. Meta-analysis on 
pharmacogenetics of platinum-based chemotherapy in non small cell 
lung cancer (NSCLC) patients. PLoS One. 2012;7(6):e38150.
 8. Mayo C, Bertran-Alamillo J, Molina-Vila MA, Gimenez-Capitan A, 
Costa C, Rosell R. Pharmacogenetics of EGFR in lung cancer: perspectives 
and clinical applications. Pharmacogenomics. 2012;13(7):789–802.
 9. Wang S, Peng L, Li J, et al. A trial-based cost-effectiveness analysis of 
erlotinib alone versus platinum-based doublet chemotherapy as first-
line therapy for eastern asian nonsquamous non-small-cell lung cancer. 
PLoS One. 2013;8(3):e55917.
 10. Ihbe-Heffinger A, Paessens B, Berger K, et al. The impact of chemo-
therapy-induced side effects on medical care usage and cost in German 
hospital care – an observational analysis on non-small-cell lung cancer 
patients. Support Care Cancer. 2013;21(6):1665–1675.
 11. Mylonaki E, Manika K, Zarogoulidis P, et al. In vivo synergistic cyto-
genetic effects of aminophylline on lymphocyte cultures from patients 
with lung cancer undergoing chemotherapy. Mutat Res. 2012;740(1–2): 
1–5.
 12. Boutsikou E, Kontakiotis T, Zarogoulidis P, et al. Docetaxel-carboplatin 
in combination with erlotinib and/or bevacizumab in patients with non-
small cell lung cancer. Onco Targets Ther. 2013;6:125–134.
 13. Zarogoulidis K, Eleftheriadou E, Kontakiotis T, et al. Long acting 
somatostatin analogues in combination to antineoplastic agents in the 
treatment of small cell lung cancer patients. Lung Cancer. 2012;76(1): 
84–88.
 14. Zarogoulidis K, Ziogas E, Papagiannis A, et al. Interferon alpha-2a 
and combined chemotherapy as first line treatment in SCLC patients: 
a randomized trial. Lung Cancer. 1996;15(2):197–205.
 15. Hohenforst-Schmidt W. Intratumoral Chemotherapy (ITC) – a forgotten 
option at least in functionally or oncologically driven palliation! Paper 
presented at: 16th WCBE 20102010.
 16. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumoral 
chemotherapy of lung cancer. Lung Cancer. 2008;61(1):1–12.
 17. Kar UK, Srivastava MK, Andersson A, et al. Novel CCL21-vault 
nanocapsule intratumoral delivery inhibits lung cancer growth. PLoS 
One. 2011;6(5):e18758.
 18. Macha HN, Freitag L. The role of brachytherapy in the treatment 
and control of central bronchial carcinoma. Monaldi Arch Chest Dis. 
1996;51(4):325–328.
 19. Freitag L, Ernst A, Thomas M, Prenzel R, Wahlers B, Macha HN. 
Sequential photodynamic therapy (PDT) and high dose brachytherapy 
for endobronchial tumour control in patients with limited bronchogenic 
carcinoma. Thorax. 2004;59(9):790–793.
 20. Porpodis K, Karanikas M, Zarogoulidis P, et al. A case of typical 
pulmonary carcinoid tumor treated with bronchoscopic therapy followed 
by lobectomy. J Multidiscip Healthc. 2012;5:47–51.
 21. Freitag L, Macha H-N, Loddenkemper R. Interventional bronchoscopic 
procedures. Eur Resp mon. 2001;17:272–304.
 22. Zarogoulidis P, Chatzaki E, Porpodis K, et al. Inhaled chemotherapy 
in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 
2012;7:1551–1572.
 23. Zarogoulidis P, Eleftheriadou E, Sapardanis I, et al. Feasibility and 
effectiveness of inhaled carboplatin in NSCLC patients. Invest New 
Drugs. 2012;30(4):1628–1640.
 24. Darwiche K, Zarogoulidis P, Karamanos NK, et al. Efficacy versus 
safety concerns for aerosol chemotherapy in non-small-cell lung 
 cancer: a future dilemma for micro-oncology. Future Oncol. 2013;9(4): 
505–525.
 25. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study 
of repeated intratumoral delivery of adenoviral p53 in patients with 
advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(11): 
1689–1699.
 26. Zarogoulidis P, Chatzaki E, Hohenforst-Schmidt W, et al. Management 
of malignant pleural effusion by suicide gene therapy in advanced stage 
lung cancer: a case series and literature review. Cancer Gene Ther. 
2012;19(9):593–600.
 27. Jia Y, Yuan M, Yuan H, et al. Co-encapsulation of magnetic Fe3O4 nano-
particles and doxorubicin into biodegradable PLGA nanocarriers for 
intratumoral drug delivery. Int J Nanomedicine. 2012;7:1697–1708.
 28. Cunha-Filho MS, Alvarez-Lorenzo C, Martinez-Pacheco R, Landin M. 
Temperature-sensitive gels for intratumoral delivery of beta- lapachone: 
effect of cyclodextrins and ethanol. ScientificWorldJournal. 2012;2012: 
126723.
 29. Ahmed M, Moussa M, Goldberg SN. Synergy in cancer treatment 
between liposomal chemotherapeutics and thermal ablation. Chem 
Phys Lipids. 2012;165(4):424–437.
 30. Horev-Drori G, Cooks T, Bittan H, et al. Local control of experimen-
tal malignant pancreatic tumors by treatment with a combination of 
chemotherapy and intratumoral 224 radium-loaded wires releasing 
alpha-emitting atoms. Transl Res. 2012;159(1):32–41.
 31. Ginsberg RJ. Resection of non-small cell lung cancer: how much and 
by what route. Chest. 1997;112(Suppl 4):203S–205S.
 32. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. 
J Natl Cancer Inst. 1996;88(17):1193–1203.
 33. Pauwels B, Korst AE, Lardon F, Vermorken JB. Combined modality 
therapy of gemcitabine and radiation. Oncologist. 2005;10(1):34–51.
 34. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin 
Oncol. 2007;25(26):4043–4050.
 35. Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. Treatment of solid 
tumors by interstitial release of recoiling short-lived alpha emitters. 
Phys Med Biol. 2007;52(16):5025–5042.
 36. Celikoglu F, Celikoglu SI. Intratumoural chemotherapy with 
5- fluorouracil for palliation of bronchial cancer in patients with severe 
airway obstruction. J Pharm Pharmacol. 2003;55(10):1441–1448.
 37. Hohenforst-Schmidt W. Intratumoral chemotherapy (ITC) as 
adjunct therapy in NSCLC iiia–iv prolongs life. Poster presented 
at:  International Conference and Exhibition on Cancer Science and 
Therapy; August 15–17, 2011; Las Vegas, NV.
 38. Bae YH. Interview with Dr You Han Bae: ligand-mediated versus 
‘passive’ targeting approaches in nanoparticle oncology research. Ther 
Deliv. 2012;3(8):933–936.
 39. Yang W, Ahmed M, Elian M, et al. Do liposomal apoptotic enhancers 
increase tumor coagulation and end-point survival in percutaneous 
radiofrequency ablation of tumors in a rat tumor model? Radiology. 
2010;257(3):685–696.
 40. Le Pivert PJ, Morrison DR, Haddad RS, et al. Percutaneous tumor 
ablation: microencapsulated echo-guided interstitial chemotherapy 
combined with cryosurgery increases necrosis in prostate cancer. 
Technol Cancer Res Treat. 2009;8(3):207–216.
 41. Lin X, Gao R, Zhang Y, et al. Lipid nanoparticles for chemotherapeutic 
applications: strategies to improve anticancer efficacy. Expert Opin 
Drug Deliv. 2012;9(7):767–781.
 42. Xie H, Goins B, Bao A, Wang ZJ, Phillips WT. Effect of intratumoral 
administration on biodistribution of 64Cu-labeled nanoshells. Int J 
Nanomedicine. 2012;7:2227–2238.
 43. Sim H, Bibee K, Wickline S, Sept D. Pharmacokinetic modeling of 
tumor bioluminescence implicates efflux, and not influx, as the bigger 
hurdle in cancer drug therapy. Cancer Res. 2011;71(3):686–692.
 44. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo 
characteristics of cationic and neutral liposomes. Int J Nanomedicine. 
2011;6:3087–3098.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
581
Intratumoral chemotherapy for lung cancer
Drug Design, Development and Therapy 2013:7
 45. Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon 
monoxide, generated by heme oxygenase-1, mediates the enhanced per-
meability and retention effect in solid tumors. Cancer Sci. 2012;103(3): 
535–541.
 46. Celikoglu F, Celikoglu SI, York AM, Goldberg EP. Intratumoral admin-
istration of cisplatin through a bronchoscope followed by irradiation for 
treatment of inoperable non-small cell obstructive lung cancer. Lung 
Cancer. 2006;51(2):225–236.
 47. Celikoglu F, Celikoglu SI, Goldberg EP. Intratumoural chemotherapy 
of lung cancer for diagnosis and treatment of draining lymph node 
metastasis. J Pharm Pharmacol. 2010;62(3):287–295.
 48. Celikoglu SI, Karayel T, Demirci S, Celikoglu F, Cagatay T. Direct injec-
tion of anti-cancer drugs into endobronchial tumours for palliation of 
major airway obstruction. Postgrad Med J. 1997;73(857):159–162.
 49. Horng G, Askari S, Choi Y, Grundfest W. Sustained Localized Drug 
Delivery In Mammalian Lung By Bronchoscopy. Paper presented at: 
American Thoracic Society 2012 International Conference; May 18–23, 
2012; San Francisco, CA.
 50. Yeh CT, Chen HC, Sung CM, et al. Retrospective comparison between a 
regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitox-
antrone for the treatment of far advanced hepatocellular carcinoma. 
BMC Cancer. 2011;11:117.
 51. Goldberg EP, Hadba AR, Almond BA, Marotta JS. Intratumoral cancer 
chemotherapy and immunotherapy: opportunities for nonsystemic pre-
operative drug delivery. J Pharm Pharmacol. 2002;54(2):159–180.
 52. Vogl TJ, Wissniowski TT, Naguib NN, et al. Activation of tumor-
specific T lymphocytes after laser-induced thermotherapy in patients 
with colorectal liver metastases. Cancer Immunol Immunother. 
2009;58(10):1557–1563.
 53. Monga SP, Wadleigh R, Sharma A, et al. Intratumoral therapy of cispla-
tin/epinephrine injectable gel for palliation in patients with obstructive 
esophageal cancer. Am J Clin Oncol. 2000;23(4):386–392.
 54. Wagai F, Kinoshita M, Shiraki R, Watanabe H, Kitamura S. [The direct 
injection of several anti-cancer drugs into the primary lung cancer lesion 
through a fiberoptic bronchoscope (author’s transl).] Nihon Kyobu 
 Shikkan Gakkai Zasshi. 1982;20(2):170–175. Japanese.
 55. Liu M, Ma P, Lu Z. [Local chemotherapy by fibrobronchoscopy for 
advanced bronchogenic carcinoma.] Zhonghua Jie He He Hu Xi Za 
Zhi. 2000;23(9):550–551. Chinese.
 56. Celikoglu SI, Celikoglu F, Goldberg EP. Endobronchial intratumoral 
chemotherapy (EITC) followed by surgery in early non-small cell lung 
cancer with polypoid growth causing erroneous impression of advanced 
disease. Lung Cancer. 2006;54(3):339–346.
 57. Nader AD. Intratumoral chemotherapy as an adjuvant to endobronchial 
brachytherapy. Chest. 2007;132(Suppl):459.
 58. Jabbardarjani H, Safara H, Kharabian S, Reza M. Endobronchial 
chemotherapy in malignant airway lesions of the lung: Report of 3 years 
experience. J Bronchology. 2007;14:242–245.
 59. Ramos HC, Ruivo I, deBrito U. Use of intratumoral cisplatinium in 
lung cancer. Experimental Pathology and Healt Science. 2008;2(2): 
45–46.
 60. He J, Ying W, Yang H, et al. Gemcitabine plus cisplatin chemotherapy 
with concurrent para-toluenesulfonamide local injection therapy for 
peripherally advanced nonsmall cell lung cancer larger than 3 cm in 
the greatest dimension. Anticancer Drugs. 2009;20(9):838–844.
 61. Brincker H. Direct intratumoral chemotherapy. Crit Rev Oncol Hematol. 
1993;15(2):91–98.
 62. Li C, Wang Y, Zhang X, Deng L, Zhang Y, Chen Z. Tumor-targeted 
liposomal drug delivery mediated by a diseleno bond-stabilized cyclic 
peptide. Int J Nanomedicine. 2013;8:1051–1062.
 63. Kosacka M, Piesiak P, Kowal A, Golecki M, Jankowska R. Galectin-3 
and cyclin D1 expression in non-small cell lung cancer. J Exp Clin 
Cancer Res. 2011;30:101.
 64. Peiris PM, Bauer L, Toy R, et al. Enhanced delivery of chemotherapy to 
tumors using a multicomponent nanochain with radio-frequency-tunable 
drug release. ACS Nano. 2012;6(5):4157–4168.
 65. Werner JA, Kehrl W, Pluzanska A, et al. A phase III placebo-controlled 
study in advanced head and neck cancer using intratumoural cisplatin/
epinephrine gel. Br J Cancer. 2002;87(9):938–944.
 66. Callahan DJ, Liu W, Li X, et al. Triple stimulus-responsive polypeptide 
nanoparticles that enhance intratumoral spatial distribution. Nano Lett. 
2012;12(4):2165–2170.
 67. Govindarajan S, Sivakumar J, Garimidi P, et al. Targeting human 
epidermal growth factor receptor 2 by a cell-penetrating peptide-
affibody bioconjugate. Biomaterials. 2012;33(8):2570–2582.
 68. Gopal V, Guruprasad K. Structure prediction and validation of an 
affibody engineered for cell-specific nucleic acid targeting. Syst Synth 
Biol. 2010;4(4):293–297.
 69. Liu Q, Li R, Zhu Z, et al. Enhanced antitumor efficacy, biodistribution 
and penetration of docetaxel-loaded biodegradable nanoparticles. 
Int J Pharm. 2012;430(1–2):350–358.
 70. Watson KD, Lai CY, Qin S, et al. Ultrasound increases nanoparticle 
delivery by reducing intratumoral pressure and increasing transport in 
epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 
2012;72(6):1485–1493.
 71. Hecht JR, Farrell JJ, Senzer N, et al. EUS or percutaneously guided 
intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for 
first-line treatment of locally advanced pancreatic cancer: a phase I/II 
study. Gastrointest Endosc. 2012;75(2):332–338.
 72. Hanna N, Ohana P, Konikoff FM, et al. Phase 1/2a, dose-escalation, 
safety, pharmacokinetic and preliminary efficacy study of intratumoral 
administration of BC-819 in patients with unresectable pancreatic 
cancer. Cancer Gene Ther. 2012;19(6):374–381.
 73. Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of 
intratumoral/intracerebral or intravenous/intracerebral administration 
of Parvovirus H-1 (ParvOryx) in patients with progressive primary or 
recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 
2012;12:99.
 74. Zheng X, Zhou F, Wu B, Chen WR, Xing D. Enhanced tumor treat-
ment using biofunctional indocyanine green-containing nanostructure 
by intratumoral or intravenous injection. Mol Pharm. 2012;9(3): 
514–522.
 75. Luo X, Xie C, Wang H, Liu C, Yan S, Li X. Antitumor activities 
of emulsion electrospun fibers with core loading of hydroxycamp-
tothecin via intratumoral implantation. Int J Pharm. 2012;425(1–2): 
19–28.
 76. Luo X, Xu G, Song H, et al. Promoted antitumor activities of acid-labile 
electrospun fibers loaded with hydroxycamptothecin via intratumoral 
implantation. Eur J Pharm Biopharm. 2012;82(3):545–553.
 77. Tsuda K, Yamanaka K, Linan W, et al. Intratumoral injection of Pro-
pionibacterium acnes suppresses malignant melanoma by enhancing 
Th1 immune responses. PLoS One. 2011;6(12):e29020.
 78. Oh SM, Oh K, Lee DS. Intratumoral administration of secondary 
lymphoid chemokine and unmethylated cytosine-phosphorothioate-
guanine oligodeoxynucleotide synergistically inhibits tumor growth 
in vivo. J Korean Med Sci. 2011;26(10):1270–1276.
 79. Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al. Intratumoral 
hu14.18-IL-2 (IC) induces local and systemic antitumor effects that 
involve both activated T and NK cells as well as enhanced IC retention. 
J Immunol. 2012;189(5):2656–2664.
 80. Akeda T, Yamanaka K, Kitagawa H, et al. Intratumoral injection of 
OK-432 suppresses metastatic squamous cell carcinoma lesion induc-
ing interferon- γ and tumor necrosis factor-α. Clin Exp Dermatol. 
2012;37(2):193–194.
 81. Betting DJ, Hurvitz SA, Steward KK, et al. Combination of cyclo-
phosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide 
successfully eradicates established B cell lymphoma. J Immunother. 
2012;35(7):534–543.
 82. Zhong H, Han B, Tourkova IL, et al. Low-dose paclitaxel prior to 
intratumoral dendritic cell vaccine modulates intratumoral cytokine 
network and lung cancer growth. Clin Cancer Res. 2007;13(18 Pt 1): 
5455–5462.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
582
Hohenforst-Schmidt et al
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2013:7
 83. Son CH, Shin DY, Kim SD, et al. Improvement of antitumor effect of 
intratumoral injection of immature dendritic cells into irradiated tumor 
by cyclophosphamide in mouse colon cancer model. J Immunother. 
2012;35(8):607–614.
 84. Galili U. Conversion of tumors into autologous vaccines by intratumoral 
injection of alpha-Gal glycolipids that induce anti-Gal/alpha-Gal epitope 
interaction. Clin Dev Immunol. 2011;2011:134020.
 85. Hamalukic M, Huelsenbeck J, Schad A, Wirtz S, Kaina B, Fritz G. 
Rac1-regulated endothelial radiation response stimulates extravasation 
and metastasis that can be blocked by HMG-CoA reductase inhibitors. 
PLoS One. 2011;6(10):e26413.
 86. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-
tumoral interstitial fluid pressure and circulating biomarkers in 
patients with refractory sarcomas (NCI protocol 6948). PLoS One. 
2012;7(2):e26331.
 87. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development 
and human disease. Nature. 2005;438(7070):946–953.
 88. Fan Y, Du W, He B, et al. The reduction of tumor interstitial fluid 
pressure by liposomal imatinib and its effect on combination therapy 
with liposomal doxorubicin. Biomaterials. 2013;34(9):2277–2288.
 89. Shayan R, Achen MG, Stacker SA. Lymphatic vessels in cancer 
metastasis: bridging the gaps. Carcinogenesis. 2006;27(9):1729–1738.
 90. Oliver G, Harvey N. A stepwise model of the development of lymphatic 
vasculature. Ann N Y Acad Sci. 2002;979:159–165; discussion 
188–196.
 91. Lardinois D, Brack T, Gaspert A, et al. Bronchoscopic radioisotope 
injection for sentinel lymph-node mapping in potentially resectable 
non-small-cell lung cancer. Eur J Cardiothorac Surg. 2003;23(5): 
824–827.
 92. Chen X, Wang X, Wang Y, et al. Improved tumor-targeting drug 
delivery and therapeutic efficacy by cationic liposome modified with 
truncated bFGF peptide. J Control Release. 2010;145(1):17–25.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
583
Intratumoral chemotherapy for lung cancer
